Prescription medication · Meglitinide
repaglinide
Also sold as Prandin. Repaglinide is used to lower blood sugar in adults with type 2 diabetes.
Data updated 2026-05-15
- 7,180
- FDA reportsLightly reported
- 22
- InteractionsSeveral interactions
- $0.08
- Generic price (NADAC)
What the data shows
repaglinide (Prandin) is a prescription Meglitinide, reported less often than most tracked drugs (7,180 FDA reports), with 22 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
repaglinide (Prandin) is a prescription Meglitinide. Repaglinide is used to lower blood sugar in adults with type 2 diabetes.
Repaglinide (Prandin) helps control blood sugar in adults with type 2 diabetes. It works best when used with diet and exercise.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$0.08/unit
Generic Available
Yes (3 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
NADAC price trail: REPAGLINIDE 0.5 MG TABLET
Same CMS presentation as the headline generic unit price above (3 effective dates). Adjacent % compares consecutive NADAC releases for this description only, not a patient out-of-pocket quote. Latest step: +4.8% vs prior release.
| Effective | NADAC / unit | vs prior | NDCs |
|---|---|---|---|
| June 19, 2024 | $0.0836/EA | - | 1 |
| October 23, 2024 | $0.0809/EA | -3.2% | 1 |
| December 18, 2024 | $0.0848/EA | +4.8% | 2 |
What it does
Repaglinide is used to lower blood sugar in adults with type 2 diabetes.
Common side effects
Low blood sugar, Upper respiratory infection, Headache
Key warnings
Repaglinide can cause low blood sugar (hypoglycemia).
The sections below are summarized in plain English from repaglinide's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Repaglinide helps your pancreas release insulin after you eat. Insulin helps move sugar from your blood into your cells. This lowers your blood sugar levels.
Side Effects (from patient reports)
Based on 7,180 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for repaglinide, by number of reports
- Hypoglycaemia
Hypoglycaemia
765 reports
- Acute Kidney Injury
Acute Kidney Injury
548 reports
- Drug Interaction
Drug Interaction
418 reports
- Diarrhoea
Diarrhoea
365 reports
- Lactic Acidosis
Lactic Acidosis
364 reports
- Dyspnoea 277
Dyspnoea
277 reports
- Nausea 259
Nausea
259 reports
- Asthenia 251
Asthenia
251 reports
- Anaemia 237
Anaemia
237 reports
- Vomiting 235
Vomiting
235 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for repaglinide each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where repaglinide sits
repaglinide has more FDA adverse-event reports than 31% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is repaglinide; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 7,180 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
7,180
Reports Mentioning Death
688
9.6% of reports — not proof of cause
Hospitalization Reports
4,308
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | HYPOGLYCAEMIA | 765 |
| 2 | ACUTE KIDNEY INJURY | 548 |
| 3 | DRUG INTERACTION | 418 |
| 4 | DIARRHOEA | 365 |
| 5 | LACTIC ACIDOSIS | 364 |
| 6 | DYSPNOEA | 277 |
| 7 | NAUSEA | 259 |
| 8 | ASTHENIA | 251 |
| 9 | ANAEMIA | 237 |
| 10 | VOMITING | 235 |
| 11 | FALL | 229 |
| 13 | FATIGUE | 212 |
| 14 | BLOOD GLUCOSE INCREASED | 206 |
| 15 | HYPERKALAEMIA | 195 |
| 17 | MALAISE | 185 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Repaglinide can cause low blood sugar (hypoglycemia). If you skip a meal, skip your dose of repaglinide to avoid low blood sugar. Do not use repaglinide with NPH-insulin. There is no proof that repaglinide lowers your risk of heart problems.
Known Drug Interactions
Table 3: Clinically Important Drug Interactions with Repaglinide Gemfibrozil Clinical Impact: Gemfibrozil significantly increased repaglinide exposures by 8.1 fold [see Clinical Pharmacology (12.3) ] Intervention: Do not administer repaglinide to patients receiving gemfibrozil [see Contraindications (4) ] . Clopidogrel Clinical Impact: Clopidogrel increased repaglinide exposures by 3.9 to 5.1 fold [see Clinical Pharmacology (12.3) ] Intervention: Avoid concomitant use of repaglinide with clopidogrel. Drugs that are known to inhibit CYP2C8 include trimethoprim, gemfibrozil, montelukast,...
Mechanism: Gemfibrozil stops your body from getting rid of repaglinide, which causes the level of repaglinide in your blood to become dangerously high.
Gastroprokinetic Agents: Cisapride Contraindicated Cisapride: [See Contraindications ( 4.2 )] Lipid-lowering agents: Lomitapide Lovastatin Simvastatin Contraindicated Lomitapide, Lovastatin, Simvastatin: Clarithromycin may increase the exposure of these drugs by inhibition of CYP3A metabolism, thereby increasing the risk of toxicities from these drugs [see Contraindications ( 4.5 ) and Warnings and Precautions ( 5.4 )] Atorvastatin, Pravastatin, Fluvastatin: [See Warnings and Precautions ( 5.4 )] Atorvastatin Pravastatin Use With Caution Fluvastatin No Dose Adjustment Hypoglycemic Agents:...
Mechanism: Clarithromycin interferes with the enzyme that processes repaglinide, which can cause the medicine to stay in your system longer and drop your blood sugar too low.
Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg (7) Cyclosporine : Limit daily dose of repaglinide to 6 mg and increase frequency of glucose monitoring when co-administered (7) CYP2C8 and CYP3A4 Inhibitors and Drugs That May Increase the Risk of Hypoglycemia : Co-administration may require repaglinide dose reductions and increased frequency of glucose monitoring (7) CYP2C8 and CYP3A4 Inducers and Drugs That May Decrease the Blood Glucose Lowering...
Mechanism: Clonidine can hide the warning signs of low blood sugar and may also cause blood sugar to drop further when taken with repaglinide.
Cyclosporine Clinical Impact: Cyclosporine increased low dose repaglinide exposures by 2.5 fold [see Clinical Pharmacology (12.3) ] Intervention: Daily maximum repaglinide dose should be limited to 6 mg, and increased frequency of glucose monitoring may be required when repaglinide is co-administered with cyclosporine. Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg (7) Cyclosporine : Limit daily dose of repaglinide to 6 mg and increase frequency...
Mechanism: Cyclosporine causes the amount of repaglinide in your blood to increase, which can make your blood sugar drop too low.
Examples: Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine Drugs That May Increase the Risk of Hypoglycemia Intervention: Repaglinide dose reductions and increased frequency of glucose monitoring may be required when co-administered.
Mechanism: Rifampin changes how your body processes repaglinide, which can increase the risk of your blood sugar dropping too low.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I do if my blood sugar gets too low?
Can I take repaglinide with other diabetes medicines?
Will repaglinide affect my weight?
What if I am taking other medications?
Can I drink alcohol while taking repaglinide?
What happens if I take too much repaglinide?
How often should I check my blood sugar?
What are the symptoms of low blood sugar?
Can I drive while taking repaglinide?
What if I have kidney problems?
What are the common side effects of repaglinide?
Does repaglinide interact with other medications?
What drug class is repaglinide?
What pregnancy or breastfeeding source fields are listed for repaglinide?
Related Medications in Meglitinide
Other drugs grouped near repaglinide - same-class peers and common alternatives.
acarbose
Precose
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes.
Compare with repaglinide →
alogliptin
Nesina
Compare with repaglinide →
bromocriptine
Cycloset
Bromocriptine (Cycloset) is a medicine that acts like dopamine in your body.
Compare with repaglinide →
canagliflozin
Invokana
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Compare with repaglinide →
colesevelam
Welchol
Colesevelam is a medicine that helps lower bad cholesterol (LDL-C) and control blood sugar in adults.
Compare with repaglinide →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for repaglinide: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 7,180.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 9.58%.
- vigabatrin Δ 0.00 pts · 14,085 reports · Anticonvulsant (GABA Transaminase Inhibitor) 9.58%death share
- alfuzosin Δ 0.04 pts · 2,222 reports · Alpha-1 Blocker (BPH) 9.54%death share
- sitagliptin Δ 0.11 pts · 70,292 reports · DPP-4 Inhibitor 9.47%death share
- trandolapril Δ 0.12 pts · 1,978 reports · ACE Inhibitor 9.71%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on repaglinide
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for repaglinide
The FDA label for repaglinide (sold under brand names such as Prandin) classifies it as a prescription-only medication in the Meglitinide class. Repaglinide is used to lower blood sugar in adults with type 2 diabetes. Official labeling lists 8 commonly reported side effects, including Low blood sugar, Upper respiratory infection, Headache.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 7,180 voluntary reports. The database also lists 22 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS shows a generic unit cost of $0.08.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: January 16, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages